Paper Details

  1. Home
  2. Paper Details

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.

Author: AttiaSteven, BauerSebastian, BlayJean-Yves, GelderblomHans, GeorgeSuzanne, HeinrichMichael C, JonesRobin L, KangYoon-Koo, Le CesneAxel, MeadeJulie, RazakAlbiruni Abdul, Ruiz-SotoRodrigo, SchöffskiPatrick, ShermanMatthew L, SuYing, TrentJonathan, WangTao, ZalcbergJohn R, von MehrenMargaret

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Ripretinib is a new tyrosine kinase inhibitor (TKI) that shows comparable effectiveness and safety to sunitinib in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib.
Paper Details　
Original Abstract of the Article :
Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746771/

データ提供：米国国立医学図書館（NLM）

Ripretinib vs. Sunitinib for Advanced Gastrointestinal Stromal Tumor (GIST)

This study ventures into the world of oncology, specifically the treatment of advanced gastrointestinal stromal tumors (GISTs). It's like exploring a vast desert of cancer treatments, seeking the most effective and safe options. The researchers compared the efficacy and safety of two tyrosine kinase inhibitors (TKIs), ripretinib and sunitinib, in patients with advanced GIST who had previously been treated with imatinib. This is like comparing two different paths through the desert, looking for the one that leads to the best outcome. Their findings suggest that ripretinib may be a more effective and safe treatment option for patients with advanced GIST who have previously been treated with imatinib. This is like discovering a new oasis in the desert, one that offers a better chance of survival and a better quality of life.

Ripretinib: A New Oasis for GIST Treatment

The study found that ripretinib was more effective and safer than sunitinib in patients with advanced GIST who had previously been treated with imatinib. This is a significant finding, as it offers a new treatment option for patients who have exhausted other options. It's like finding a new source of water in a parched desert, offering hope for survival and well-being.

A New Path Through the Desert of GIST

The study highlights the importance of ongoing research in the field of oncology, seeking new and innovative treatments for cancer. This is like constantly searching for new oases in the vast desert of cancer, looking for the most effective ways to combat the disease. The researchers' findings are a testament to the commitment of scientists and clinicians to improve the lives of patients with cancer.

Dr.Camel's Conclusion

This study is a beacon of hope for patients with advanced GIST. It's a reminder that the desert of cancer treatment is vast and complex, but that with continued research and innovation, we can find new and effective solutions. The findings offer a new path to better health and a better quality of life for those who are battling this challenging disease.

Date :
  1. Date Completed 2022-11-30
  2. Date Revised 2023-02-12
Further Info :

Pubmed ID

35947817

DOI: Digital Object Identifier

PMC9746771

Related Literature

Article Analysis
・Effects of ripretinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.